Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1131849

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to improve NHS waiting times for cancer patients.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	263683
answer	answer is ministerial correction date of answer 19/06/2019 answer text <p>The NHS Long Term Plan sets out plans to improve early cancer diagnosis, and a new ambition that, by 2028, the proportion of cancers diagnosed at stages one and two will rise from around half to three-quarters of cancer patients. This will be achieved through raising greater awareness of symptoms of cancer, accelerating access to diagnosis and treatment, maximising the number of cancers that are identified through screening, and harnessing new innovations in technology. A radical overhaul of the way diagnostic services are delivered will ensure that people can get their diagnosis more quickly, including the roll-out of new Rapid Diagnostic Centres across the country to upgrade and bring together the latest diagnostic equipment and expertise.</p><p> </p><p>The independent cancer taskforce recommended the introduction of a new faster diagnosis standard to ensure that people receive a life changing confirmation of whether or not they have cancer within 28 days. This proposed new standard is being considered as part of the clinical review of National Health Service access standards currently being undertaken by NHS England.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/06/2019 14:26:47 answering member 4455 label Biography information for Seema Kennedy
tabling member	298 label Biography information for Steve McCabe

1131187

registered interest
date	11/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the UK Government’s response to the resolution on improving the transparency of markets at the 72nd World Health Assembly in Geneva on the ability of people in the UK to access medicines.
tabling member constituency	Portsmouth South
tabling member printed	Stephen Morgan
uin	263223
answer	answer is ministerial correction date of answer 19/06/2019 answer text <p>The United Kingdom participates in various transparency initiatives, including the European Integrated Price Information Database, the World Health Organization’s Pharmaceutical Pricing Reimbursement Information Network, and the Global Fund Price and Quality Database. The UK has a long-established and globally-recognised track record of assessing the price of new, innovative medicines according to their clinical value, rather than pricing by their development costs or international reference prices.</p><p>We believe that is the right approach: ensuring the development of the best medicines in areas of high unmet need are rewarded. The Government could not, therefore, agree to a resolution which had the potential to increase medicines prices and reduce patient access, by reducing the ability of the National Health Service to undertake commercial negotiations with pharmaceutical companies on the price of new medicines.</p><p>The approach taken by the NHS has meant we were the first country in Europe to offer innovative CAR-T therapies, alongside many other new medicines.</p><p> </p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/06/2019 14:20:00 answering member 4455 label Biography information for Seema Kennedy
tabling member	4653 label Biography information for Stephen Morgan

1131208

registered interest
date	11/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to tackle shortages of (a) Adalat, (b) Nifedipine and (c) other common medicines.
tabling member constituency	Bury North
tabling member printed	James Frith
uin	263235
answer	answer is ministerial correction date of answer 19/06/2019 answer text <p>The vast majority of medicines are not subject to supply problems and every day over 2 million prescription items are successfully dispensed in England.</p><p>Where problems do occur the Department’s Medicines Supply Team has well established procedures to deal with medicine shortages and works closely with all stakeholders to help prevent shortages and to ensure that the risks to patients are minimised when they do arise.</p><p>We are aware of ongoing supply issues with the Adalat range of the drug nifedipine due to manufacturing capacity constraints. We have been working closely with all suppliers of generic and other brands of nifedipine to maintain overall supply of this medicine to patients and have provided regular updates about the situation to the National Health Service.</p><p>We will continue to work closely with all manufacturers of nifedipine preparations to monitor the overall supply situation to ensure supplies continue to remain available.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/06/2019 14:22:30 answering member 4455 label Biography information for Seema Kennedy
tabling member	4637 label Biography information for James Frith

1131255

registered interest
date	11/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Obesity
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to tackle obesity.
tabling member constituency	North Antrim
tabling member printed	Ian Paisley
uin	263150
answer	answer is ministerial correction date of answer 19/06/2019 answer text <p>I refer the hon. Member to the answer given by the former Parliamentary Under-Secretary of State for Public Health and Primary Care (Steve Brine MP) to the hon. Member for Cardiff Central (Jo Stevens MP) on 28 February 2019 to Question <a href="https://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2019-02-25/225540/" target="_blank">225540</a>.</p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/06/2019 14:17:06 answering member 4455 label Biography information for Seema Kennedy
tabling member	4129 label Biography information for Ian Paisley

1131293

registered interest
date	11/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many companies are licensed to sell cannabis products to the NHS.
tabling member constituency	Ross, Skye and Lochaber
tabling member printed	Ian Blackford
uin	263171
answer	answer is ministerial correction date of answer 19/06/2019 answer text <p>Any company meeting the standards for the manufacture of unlicensed medicinal products, can supply cannabis-based products for medicinal use.</p><p> </p><p>Cannabis-based products for medicinal use are Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001, which means that manufacturers, importers and distributors of these products must hold valid Home Office and Medicines and Healthcare products Regulatory Agency (MHRA) licences for the relevant activities which will include possession, supply and production of controlled drugs. Where products are sourced from abroad, importers must obtain an import licence from the Home Office and non-objection to import from the MHRA for each individual import of a controlled drug.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/06/2019 09:39:54 answering member 4455 label Biography information for Seema Kennedy
tabling member	4390 label Biography information for Ian Blackford

1131321

registered interest
date	11/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress he has made on ensuring that medical cannabis is available to people who need it.
tabling member constituency	Birkenhead
tabling member printed	Frank Field
uin	263063
answer	answer is ministerial correction date of answer 19/06/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s ‘Specialist Register’ to prescribe cannabis-based products for medicinal use, where clinically appropriate and in the best interest of patients.</p><p>Interim clinical guidance has been issued by the Royal College of Physicians, the British Paediatric Neurology Association and the Association of British Neurologists to support doctors looking to prescribe cannabis-based products. The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of cannabis-based medicinal products, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for delivering such guidance.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/06/2019 14:21:18 answering member 4455 label Biography information for Seema Kennedy
tabling member	478 label Biography information for Lord Field of Birkenhead

1131323

registered interest
date	11/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Diseases: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the merits for his Department's policies of the recommendation by the Committee on Climate Change in its Net Zero report to switch NHS patients to (a) dry powder and (b) low-global warming inhalers by 2027 to help the NHS meet its carbon targets.
tabling member constituency	Swansea West
tabling member printed	Geraint Davies
uin	263022
answer	answer is ministerial correction date of answer 19/06/2019 answer text <p>NHS England and NHS Improvement is currently reviewing cost and system pressures from changing prescribing practice linked to lower carbon inhalers and potential medication change impacts for patients. The NHS Long Term Plan has committed to a reduction in the carbon impact of inhalers of 4% of the total National Health Service carbon reduction required over the next 10 years to meet the current Climate Change Act targets.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/06/2019 14:16:14 answering member 4455 label Biography information for Seema Kennedy
tabling member	155 label Biography information for Geraint Davies

1130973

registered interest
date	10/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle the rise in the incidence of cancer in young people under 25.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	262372
answer	answer is ministerial correction date of answer 19/06/2019 answer text <p>Cancer incidence rates over the last ten years for people under 25 years old show a minimal increase in absolute numbers. Unlike with many adult cancers, lifestyle-related risk factors (such as smoking) do not influence a young person’s risk of developing cancer so cancers are less preventable. The small increase in incidence therefore reflects changes in demographics rather than relative risk of having cancer at any given age.</p><p>As such, our focus is on research and ensuring that children and young people get the very best treatment and care if they do develop cancer. The NHS Long Term Plan has a series of commitments to improve outcomes for all cancer patients, including children and young people with cancer. For example, the National Health Service will actively support children and young people to take part in clinical trials, so that participation among children remains high, and among teenagers and young adults rises to 50% by 2025. Also, from 2019, the NHS will begin to offer all children with cancer whole genome sequencing to enable more comprehensive and precise diagnosis, and access to more personalised treatments.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/06/2019 14:14:53 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon